Guide · 8 min
Which antihistamine is actually right for you?
Not all hay fever tablets work the same way — here's what the science says
In short
Second-generation antihistamines are superior to first-generation agents across multiple pharmacological dimensions: they demonstrate minimal blood-brain barrier penetration (resulting in a non-sedating profile), exhibit selective H1-receptor antagonism with negligible muscarinic blockade, and…
You've probably been taking antihistamines for years. But are you taking the right one?
For most people with hayfever, antihistamines are the first thing they reach for when the pollen hits. They're cheap, widely available, and — for many — genuinely helpful. But walk into any pharmacy and you'll be confronted with an overwhelming wall of choices: different generations, different active ingredients, branded versus generic, tablets versus eye drops. The guidance you receive rarely goes beyond "take one of these."
The science, it turns out, has a lot more to say. And some of it might surprise you.
The science: what antihistamines actually do
To understand why some antihistamines work better for you than others, it helps to know what they're actually doing in your body.
When your immune system encounters pollen, it triggers mast cells — specialised immune sentinels — to release histamine. That histamine then binds to H1 receptors on nerve endings, blood vessels, and glandular cells in your nose, eyes, and airways, triggering the familiar cascade: sneezing, itching, runny nose, watery eyes.
Antihistamines don't simply block histamine from reaching these receptors. More precisely, they act as inverse agonists — they bind to the H1 receptor and actively suppress its baseline activity, stabilising it in an "off" state (Simons & Simons, 2008). Beyond this direct receptor effect, research also shows that second-generation antihistamines — particularly cetirizine, loratadine, and desloratadine — carry additional anti-inflammatory properties: suppressing Th2 cytokines like IL-4, reducing proinflammatory mediators like IL-6 and TNF-α, and potentially modulating the regulatory T cell balance (Baroody & Naclerio, 2000). This means their benefit may extend beyond simply quietening the acute histamine signal.
First versus second generation: a meaningful difference
The distinction between "old" and "new" antihistamines isn't just marketing. It reflects genuinely different pharmacology.
First-generation agents — think diphenhydramine (the active ingredient in many "PM" cold remedies) and chlorpheniramine — are small, lipid-soluble molecules that cross the blood-brain barrier readily. Once in the brain, they block not just H1 receptors but also muscarinic, serotonergic, and adrenergic receptors, producing sedation, dry mouth, blurred vision, and measurable cognitive impairment (Simons & Simons, 2008). A meta-analysis by Bender et al. (2003) confirmed that these agents cause statistically significant psychomotor slowing and sedation compared to placebo — effects that drivers and anyone operating machinery should take seriously.
Second-generation agents — cetirizine, loratadine, fexofenadine, levocetirizine, bilastine — were engineered to address these problems. They're larger, less lipophilic molecules, and many are actively pumped out of the brain by P-glycoprotein efflux transporters. The result: peripheral H1 selectivity, once-daily dosing (12–24 hour duration versus 4–6 hours for first-generation), and a dramatically improved side-effect profile.
Not all second-generation antihistamines are equal
Here's where things get more nuanced — and personally relevant.
Cetirizine, loratadine, and fexofenadine all produce roughly comparable reductions in total nasal symptom scores (approximately 30–50% improvement versus placebo), with onset within 1–3 hours (Horak et al., 2001). But they differ in one important dimension: sedation risk.
Cetirizine achieves around 20–30% central H1 receptor occupancy — enough to cause drowsiness in approximately 10–20% of users. A four-week RCT (n=83) found fexofenadine was superior to both levocetirizine and chlorpheniramine on standardised cognitive and psychomotor measures (Hindmarch, 2002). Loratadine sits between the two, with low but detectable CNS penetration in some individuals.
Fexofenadine, by contrast, is almost entirely excluded from the CNS — achieving less than 5% central H1 occupancy. If your work requires sustained concentration, or you've ever felt foggy after a morning antihistamine, switching to fexofenadine may make a noticeable difference.
There's one potential trade-off: an Environmental Exposure Unit study (Day et al., 2004) suggested cetirizine may have a slightly longer duration of antihistamine effect than fexofenadine at 21–24 hours post-dose. For most people this is unlikely to matter, but if you find fexofenadine wears off before your next dose, it's worth noting.
Bilastine: the newer option
Bilastine 20mg is a more recent addition to the second-generation family, with a particularly high H1 receptor affinity — approximately 3–6 times greater than fexofenadine. A systematic review and meta-analysis by Randhawa et al. (2022) confirmed significant improvements in total nasal symptom scores versus placebo, and its CNS penetration profile is broadly comparable to fexofenadine — making it a non-sedating option. Direct head-to-head data against loratadine specifically are limited, so it's hard to make a definitive ranking, but bilastine represents a strong alternative for those who haven't found other second-generation agents adequate.
Combining antihistamines with other treatments
For many people with moderate-to-severe hayfever, a single antihistamine isn't enough — and the evidence strongly supports combining it with other therapies.
Intranasal corticosteroids (INCSs): A 2024 network meta-analysis by Sousa-Pinto et al. (2024), pooling 151 RCTs, confirmed that combining an antihistamine with an INCS — particularly the fixed-combination azelastine-fluticasone nasal spray — produces greater improvements in nasal and ocular symptoms than either treatment alone. The mechanism makes intuitive sense: corticosteroids suppress the underlying inflammatory cascade (mast cell activation, eosinophilia, mucosal swelling) while antihistamines rapidly block the symptomatic histamine signal. ARIA 2020 guidelines endorse this combination for moderate-to-severe allergic rhinitis. No meaningful additional safety concerns have been identified.
Leukotriene receptor antagonists (LTRAs): Adding montelukast to an antihistamine provides further, complementary benefit — particularly for nasal congestion, which histamine blockade alone often fails to adequately address. A systematic review and meta-analysis by Seresirikachorn et al. (2019) found statistically significant improvements in daytime nasal symptom scores when montelukast was added to an H1 antihistamine, with levocetirizine-montelukast combinations showing broad symptom coverage. The reasoning: histamine and leukotrienes are distinct but additive inflammatory pathways, so blocking both produces additive relief without compounding side effects.
What about your eyes?
If ocular symptoms — itching, redness, tearing — are a significant part of your hayfever picture, this matters: topical antihistamine eye drops outperform oral antihistamines for eye symptoms, both in speed and magnitude of relief.
Multiple RCTs using conjunctival allergen challenge models confirm that topical agents like olopatadine, emedastine, and levocabastine achieve higher concentrations directly at the conjunctival surface — where mast cells are degranulating — than systemic oral agents can deliver via circulation (Davies et al., 1996; Bielory, 2002). Some modern topical agents (olopatadine, alcaftadine) also stabilise mast cells, providing a dual-mechanism advantage. If you're relying on oral antihistamines for sore, itchy eyes, adding a topical antihistamine drop is likely to give you noticeably better relief.
Branded versus generic: should you pay more?
The short answer: almost certainly not. Bioequivalence studies of generic fexofenadine (Mendoza et al., 2007) and pharmaceutical quality assessments of generic cetirizine confirm comparable pharmacokinetics to branded equivalents. Regulatory standards require generics to deliver 80–125% of the branded product's AUC and peak concentration — and since antihistamines have a wide therapeutic index, these minor variations don't translate to clinical differences. Save the money.
What this means for you
Your choice of antihistamine isn't trivial — it has real implications for how alert you feel during pollen season, how well your symptoms are controlled, and whether your eyes get the targeted relief they need.
If you're currently using a first-generation antihistamine (check the box — if it says "may cause drowsiness", that's the clue), switching to a second-generation agent is almost always the right move for daytime use. If you're on a second-generation agent but still feel foggy, fexofenadine or bilastine are your lowest-CNS-impact options. And if your symptoms are moderate to severe — or if an antihistamine alone isn't cutting it — combining it with a nasal corticosteroid spray is backed by strong, consistent evidence.
The evidence landscape: what we know, and what we don't
The broad differences between antihistamine generations are well-established, with high-quality evidence and strong consensus. The comparative efficacy of specific second-generation agents (cetirizine versus loratadine versus fexofenadine) is supported by moderate-quality evidence — there are no definitive three-way head-to-head RCTs, so precise rankings are somewhat inferential.
For combination therapies, the evidence for antihistamine plus intranasal corticosteroid is strong (though ARIA's own confidence rating is "low to very low" for some sub-comparisons, reflecting the heterogeneity of included trials). Evidence for antihistamine plus montelukast is moderate — consistent but with smaller effect sizes.
A few areas remain genuinely understudied: how pharmacogenomic variation affects individual responses (CYP3A4 polymorphisms affect loratadine metabolism, for instance), long-term cognitive effects of regular cetirizine use, and optimal management for children and older adults. Haelo will keep tracking the emerging evidence on all of these.
What Haelo recommends
1. Switch away from first-generation antihistamines for daytime use. Diphenhydramine and chlorpheniramine impair cognition and reaction times. Unless a clinician has specifically recommended one for a short-term purpose (such as sedation for severe itch at night), a second-generation agent will serve you better.
2. If cognitive sharpness matters to you, choose fexofenadine or bilastine first. These have the lowest CNS penetration in the second-generation class. Cetirizine and levocetirizine are also far safer than first-generation agents, but carry a modest sedation risk for some people.
3. If your symptoms are moderate-to-severe, add an intranasal corticosteroid. Starting your INCS 1–2 weeks before your personal pollen season peaks gives it time to build its full anti-inflammatory effect. An antihistamine plus INCS combination is the most evidence-backed dual approach for hayfever.
4. If congestion is your dominant symptom, ask about montelukast. Antihistamines are less effective for nasal blockage than for itching and sneezing — leukotrienes are the bigger driver of congestion. Adding montelukast addresses this gap.
5. If your eyes are suffering, use topical antihistamine drops. Don't rely on oral antihistamines alone for ocular symptoms. An eye drop delivers targeted relief faster and more effectively at the conjunctival surface.
6. Generic is fine. Equivalent active ingredient, equivalent pharmacokinetics, significantly lower cost.
7. Track your response. Individual variation in antihistamine response is real. What works brilliantly for one person may underwhelm another. Use Haelo to log which agents help most, so you can build a genuinely personalised protocol season by season.
The evidence
What the research actually says
Each answer below is drawn from a graded research review. Confidence reflects the strength of the underlying evidence, not how confident we feel about it.
What are the key differences between first-generation and second-generation antihistamines?
Second-generation antihistamines are superior to first-generation agents across multiple pharmacological dimensions: they demonstrate minimal blood-brain barrier penetration (resulting in a non-sedating profile), exhibit selective H1-receptor antagonism with negligible muscarinic blockade, and provide a longer duration of action (12–24 hours vs. 4–6 hours), enabling once-daily dosing. First-generation agents, while still clinically useful in select scenarios such as severe pruritus in atopic dermatitis, are characterized by CNS sedation, anticholinergic side effects, cognitive and psychomotor impairment, and a less favorable safety profile including risk of toxicity. Both generations act as inverse agonists at the H1 receptor rather than simple competitive antagonists, stabilizing the receptor in its inactive state.
How it works
First-generation antihistamines are lipophilic, low-molecular-weight compounds that readily cross the blood-brain barrier and bind non-selectively to H1, muscarinic, serotonergic, and adrenergic receptors, producing their broad side-effect profile. Second-generation agents are engineered to be more lipophobic, have higher molecular weight, and may be substrates for P-glycoprotein efflux transporters, collectively restricting CNS penetration and conferring selective peripheral H1 inverse agonism.
Confidence: high
How do cetirizine, loratadine, and fexofenadine compare in efficacy and side effects?
Cetirizine, loratadine, and fexofenadine demonstrate broadly comparable efficacy in reducing allergic rhinitis symptoms (approximately 30-50% improvement in total symptom scores versus placebo), with all three achieving rapid onset within 1-3 hours and 24-hour coverage. However, cetirizine shows a modest but clinically meaningful sedation disadvantage, with drowsiness reported in approximately 10-20% of patients and measurable CNS H1 receptor occupancy, while fexofenadine and loratadine are effectively non-sedating. Evidence from Environmental Exposure Unit studies also suggests cetirizine may have a longer duration of effect than fexofenadine at 21-24 hours post-dose, representing a potential efficacy advantage in some patients.
How it works
All three agents competitively antagonize peripheral H1 receptors to block histamine-mediated rhinitis symptoms, but differ critically in CNS penetration: cetirizine achieves ~20-30% central H1 receptor occupancy due to partial blood-brain barrier permeability, while fexofenadine and loratadine are actively excluded from the CNS via P-glycoprotein efflux transporters, resulting in less than 5% central occupancy and negligible sedation.
Confidence: moderate
What is the mechanism of action of H1-receptor antagonists in allergic rhinitis?
H1-receptor antagonists act primarily as inverse agonists at H1-receptors on nerve endings, smooth muscle, and glandular cells, blocking histamine-mediated symptoms of allergic rhinitis such as pruritus, sneezing, rhinorrhea, and vasodilation. Beyond competitive histamine blockade, multiple studies indicate these agents possess additional anti-inflammatory and immunomodulatory properties, including suppression of Th2 cytokines (e.g., IL-4), modulation of CD4+ T lymphocyte subsets, and reduction of proinflammatory mediators such as IL-6 and TNF-α. Second-generation agents (e.g., cetirizine, loratadine, desloratadine, levocetirizine) deliver these effects with minimal CNS penetration compared to first-generation antihistamines.
How it works
Allergen cross-linking of IgE on mast cells and basophils triggers degranulation and histamine release; H1-antagonists function as inverse agonists by binding H1-receptors and suppressing both histamine-stimulated and constitutive receptor activity, thereby preventing downstream signaling cascades responsible for nasal inflammation. Additional immunomodulatory effects — including upregulation of regulatory T cells and inhibition of Th2-skewed cytokine production — may contribute to sustained clinical benefit beyond acute histamine blockade.
Confidence: high
How does bilastine compare to other second-generation antihistamines for hayfever?
Bilastine 20mg demonstrates comparable or superior efficacy to other second-generation antihistamines (cetirizine, levocetirizine, fexofenadine, desloratadine) for reducing allergic rhinitis symptoms, with significant improvements in Total Nasal Symptom Scores versus placebo confirmed by systematic review and meta-analysis. It offers a favorable non-sedating profile due to minimal blood-brain barrier penetration, making it broadly comparable to fexofenadine and desloratadine in terms of CNS safety, and potentially preferable to cetirizine which carries higher sedation risk. Direct head-to-head RCT data against loratadine and desloratadine specifically in allergic rhinitis remain limited, constraining definitive comparative conclusions.
How it works
Bilastine acts as a highly selective H1-receptor antagonist with approximately 3–6 times greater H1 affinity than fexofenadine, competitively blocking histamine-mediated nasal and ocular inflammatory responses. Its high molecular weight (463.61 g/mol) and P-glycoprotein substrate status restrict central nervous system penetration, explaining its non-sedating profile.
Confidence: moderate
What are the cognitive and sedation effects of different antihistamine classes?
First-generation antihistamines (e.g., diphenhydramine, chlorpheniramine) cause significant, well-documented cognitive impairment, psychomotor slowing, and sedation due to extensive CNS penetration across the blood-brain barrier. Second-generation agents (cetirizine, loratadine, levocetirizine) demonstrate substantially reduced but not entirely absent sedative and cognitive effects, while fexofenadine (third-generation) appears largely nonsedating and may confer cognitive advantages over both prior generations. A 4-week RCT (n=83) confirmed fexofenadine's superiority over levocetirizine and chlorpheniramine on standardized cognitive and psychomotor measures.
How it works
First-generation antihistamines freely cross the blood-brain barrier due to high lipophilicity, blocking central H1 receptors and augmenting GABAergic inhibition to reduce arousal and impair cognition. Second- and third-generation agents have reduced CNS penetration via lower lipophilicity and active P-glycoprotein efflux transport, with fexofenadine achieving near-complete exclusion from the CNS.
Confidence: high
How quickly do different antihistamines reach peak effectiveness after dosing?
Antihistamines generally reach peak plasma concentrations within 1-3 hours after oral administration, though there is meaningful variation between agents. Second-generation antihistamines like cetirizine reach Tmax rapidly (0.5-1 hour), while others such as bilastine (1.1-1.4 hours), loratadine, and fexofenadine follow at 1-3 hours; first-generation agents are similarly absorbed quickly but their longer half-lives (e.g., ~20 hours for chlorpheniramine) can prolong CNS effects. Clinical onset of symptom relief, as measured by histamine wheal-and-flare suppression, broadly aligns with these pharmacokinetic profiles, with meaningful antihistaminic activity typically observed within 1-2 hours post-dose.
How it works
H1-receptor antagonists are absorbed through the gastrointestinal tract and competitively block peripheral and, for first-generation agents, central H1 receptors; peak receptor occupancy and pharmacodynamic effect correlate broadly with peak plasma concentrations, though tissue distribution and receptor binding kinetics can create a slight lag between Tmax and maximal clinical effect. Second-generation agents generally have lower CNS penetration due to P-glycoprotein efflux and protein binding characteristics, confining their primary effects to peripheral H1 receptors.
Confidence: moderate
Can antihistamines be safely combined with intranasal corticosteroids?
Multiple systematic reviews and meta-analyses consistently demonstrate that combining antihistamines (particularly intranasal formulations) with intranasal corticosteroids is both safe and more effective than either monotherapy alone for allergic rhinitis, with fixed-combination azelastine-fluticasone showing the greatest improvements in total nasal and ocular symptom scores and quality-of-life measures. A 2024 network meta-analysis of 151 RCTs (Sousa-Pinto et al.) confirmed superior efficacy of the fixed combination, especially in seasonal allergic rhinitis, and ARIA 2020 guidelines endorse this approach for moderate-to-severe disease. No significant additional safety signals or drug interactions have been identified beyond those associated with individual agents.
How it works
Intranasal corticosteroids suppress the underlying eosinophilic and inflammatory cascade (reducing cytokine release, mast cell activation, and mucosal edema) via glucocorticoid receptor-mediated gene regulation, while antihistamines competitively block H1 receptors to provide rapid relief of histamine-mediated symptoms such as sneezing, pruritus, and rhinorrhea. This complementary dual-pathway inhibition addresses both the early-phase histamine response and the late-phase inflammatory response, producing additive symptomatic benefit.
Confidence: high
What role do leukotriene receptor antagonists play alongside antihistamines for hayfever?
Combination therapy with leukotriene receptor antagonists (LTRAs), primarily montelukast, added to H1-antihistamines demonstrates superior efficacy over either monotherapy alone for allergic rhinitis, particularly in reducing daytime nasal symptom scores (TNSS) and individual symptoms such as nasal congestion, sneezing, and rhinorrhea. Meta-analyses of RCTs show statistically significant improvements in daytime symptoms (SMD ~0.25) and TNSS versus monotherapy, with levocetirizine-montelukast combinations showing the broadest symptom coverage. Benefits to nighttime symptoms and quality of life (RQLQ) are less consistent and generally smaller in magnitude.
How it works
Histamine and leukotrienes represent distinct but complementary inflammatory pathways in allergic rhinitis: antihistamines (H1 antagonists) primarily attenuate early-phase responses including sneezing, itching, and rhinorrhea, while LTRAs such as montelukast block cysteinyl leukotriene receptors (CysLT1), suppressing leukotriene-mediated late-phase inflammation, nasal congestion, mucus secretion, and bronchoconstriction. Their dual blockade provides additive symptom control without overlapping mechanisms or compounding toxicity.
Confidence: moderate
Are there clinically meaningful differences between branded and generic antihistamines?
Available evidence indicates no clinically meaningful differences between branded and generic second-generation antihistamines (cetirizine, loratadine, fexofenadine) for allergic rhinitis treatment. Bioequivalence studies, such as the fexofenadine crossover trial by Mendoza et al. and quality assessments of cetirizine generics, confirm comparable pharmacokinetic parameters and pharmaceutical quality between formulations. A German practice survey (Klimek et al., n=1,243) suggested patients switching from generic to branded third-generation antihistamines reported improved outcomes, though this was an uncontrolled observational study with significant methodological limitations.
How it works
Regulatory bioequivalence standards (FDA/EMA 80–125% similarity in AUC and C_max) ensure generics deliver the same active ingredient at equivalent systemic exposure, producing identical H1-receptor occupancy and histamine suppression. Since antihistamines have a wide therapeutic index and their efficacy depends on receptor binding rather than narrow concentration thresholds, minor pharmacokinetic variation within accepted limits is unlikely to translate into clinical differences.
Confidence: moderate
What is the evidence for antihistamine eye drops vs oral antihistamines for ocular symptoms?
Topical antihistamine eye drops demonstrate superior efficacy over oral antihistamines for ocular symptoms (itching, redness, tearing) in allergic conjunctivitis, with faster onset due to direct application at the ocular surface. Multiple RCTs using conjunctival allergen challenge models confirm topical agents (emedastine, olopatadine, levocabastine) outperform oral agents (loratadine) for early-phase ocular symptom relief. Combination therapy (topical eye drops plus oral antihistamine) provides additive benefit over oral monotherapy without increased adverse events.
How it works
Topical eye drops achieve direct, high-concentration H1 receptor blockade at the conjunctival surface where mast cell degranulation and histamine release occur, bypassing the pharmacokinetic limitations of systemic distribution that result in lower, delayed tear concentrations with oral agents. Some modern topical agents (e.g., olopatadine, alcaftadine) also possess mast cell stabilizing properties, providing dual-mechanism ocular protection.
Confidence: moderate
Where the evidence runs out
Long-term comparative effectiveness data between specific second-generation agents (e.g., cetirizine vs. loratadine vs. fexofenadine) in allergic rhinitis remain limited, and inter-individual variability in CNS penetration and response among second-generation agents is not fully characterized. Additionally, the clinical relevance of inverse agonism versus simple antagonism for therapeutic outcomes has not been definitively established in large head-to-head trials. Direct three-way head-to-head RCTs comparing all three agents simultaneously in the same trial are scarce, limiting definitive efficacy rankings. Long-term comparative data beyond 6 months, pediatric-specific safety comparisons, and studies accounting for individual pharmacogenomic variation in metabolism (e.g., CYP3A4 polymorphisms affecting loratadine) remain insufficient. The precise relative contribution of immunomodulatory mechanisms (Th2 suppression, Treg upregulation) versus direct H1 blockade to overall clinical efficacy remains incompletely quantified, and head-to-head comparative data on receptor binding kinetics and onset-of-action across individual second- and third-generation agents are limited in the available literature. Long-term effects of sustained antihistamine use on the Th1/Th2 balance and disease modification have not been rigorously established in large controlled trials. No large-scale phase III RCTs or pooled meta-analyses directly compare bilastine against loratadine or desloratadine in allergic rhinitis, and most head-to-head evidence derives from small single-centre trials (n=57–114), predominantly from Indian populations, limiting generalisability. Long-term efficacy data, paediatric-specific evidence, and quality-of-life outcomes across seasonal versus perennial allergic rhinitis subtypes are also insufficiently studied. Long-term cognitive outcome data beyond 4 weeks are limited, and direct head-to-head comparisons involving loratadine and newer agents like bepotastine require replication in larger, more diverse populations. Pediatric and elderly subgroups are understudied, and it remains unclear whether the modest cognitive impairment observed with cetirizine/levocetirizine has meaningful real-world functional consequences. Precise, head-to-head comparative Tmax and onset-of-effect data using standardized pharmacodynamic endpoints (e.g., wheal-and-flare suppression) are lacking for many agents, particularly older first-generation antihistamines where pharmacokinetic data remain sparse. Additionally, the influence of patient-level factors such as food intake, genetic polymorphisms (e.g., C3435T), age, and formulation type on time-to-peak effectiveness has not been systematically characterized across the drug class. The certainty of evidence underpinning ARIA recommendations for combination therapy is rated low to very low, and few head-to-head RCTs directly compare active combination regimens against one another or assess long-term safety outcomes such as epistaxis rates or hypothalamic-pituitary-adrenal axis effects. Evidence is also less robust for perennial allergic rhinitis compared to seasonal forms, and most data derive from patients aged ≥12 years, limiting conclusions for pediatric populations. Nighttime symptom relief and quality-of-life benefits remain inconsistent across meta-analyses, and there is limited direct head-to-head evidence comparing different antihistamine-LTRA combinations (e.g., montelukast-levocetirizine versus montelukast-fexofenadine). Long-term RCTs in diverse populations, including children and perennial rhinitis patients, are insufficient to fully characterize durability and safety of combination therapy. No large, high-quality head-to-head RCTs directly comparing specific branded versus generic antihistamine formulations in allergic rhinitis patients exist, meaning equivalence is inferred primarily from regulatory bioequivalence data and indirect evidence rather than clinical outcome trials. Additionally, the potential impact of differing inactive excipients on absorption or tolerability in sensitive subpopulations (e.g., those with food allergies or intolerances) remains inadequately studied. No large-scale meta-analyses directly pooling topical vs. oral antihistamine head-to-head RCTs have been identified, and quantitative effect sizes (e.g., percentage symptom reduction) are poorly reported across studies. Evidence is limited for modern topical agents (e.g., cetirizine 0.24% ophthalmic), long-term combination therapy, and severe ocular allergy phenotypes such as atopic keratoconjunctivitis.
References
- 1.Simons F.R., Simons K. · 2008 · H1 Antihistamines: Current Status and Future Directions
- 2.Baroody F., Naclerio R. · 2000 · Antiallergic effects of H1-receptor antagonists
- 3.Bender B., Berning S., Dudden R. · 2003 · Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis
- 4.Horak F., Stübner P., Zieglmayer R. · 2001 · Controlled Comparison of the Efficacy and Safety of Cetirizine 10 mg o.d. and Fexofenadine 120 mg o.d. in Reducing Symptoms of Seasonal Allergic Rhinitis
- 5.Hindmarch I. · 2002 · CNS effects of antihistamines: is there a third generation of non-sedative drugs?
- 6.Randhawa A.S., Mohd Noor N., Md Daud M.K. · 2022 · Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis
- 7.Sousa-Pinto B., Vieira R., Brozek J. et al. · 2024 · Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis
- 8.Seresirikachorn K., Chitsuthipakorn W., Kanjanawasee D. · 2019 · Leukotriene Receptor Antagonist Addition to H1-Antihistamine Is Effective for Treating Allergic Rhinitis: A Systematic Review and Meta-analysis
- 9.Bielory L. · 2002 · Role of antihistamines in ocular allergy
- 10.Mendoza L.M., Begany P., Dyrhonová M. · 2007 · Bioequivalence of two fexofenadine formulations in healthy human volunteers after single oral administration
This article is general information about hayfever, not medical advice. It should not replace guidance from your GP, pharmacist or allergy specialist — particularly if you are pregnant, treating a child, or managing asthma alongside hayfever. Read our medical disclaimer.
